FDA Changes Bioequivalence Requirements For Vancomycin
This article was originally published in The Pink Sheet Daily
Executive Summary
ViroPharma, marketer of Lilly’s Vancocin, “strongly disagrees” with FDA’s decision and files a citizen petition challenging it.